Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trials and external validity.

B Kinosian1, H Glick

  • 1Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peanut in the lung.

Clinical proceedings - Children's Hospital of the District of Columbia·2010
Same author

Principles of effectiveness trials and their implementation in VA Cooperative Study #430: 'Reducing the efficacy-effectiveness gap in bipolar disorder'.

Journal of affective disorders·2002
Same author

A claims data approach to defining an episode of care.

Pharmacoepidemiology and drug safety·2002
Same author

Blood lead in children and its determinants in Nagpur, India.

International journal of occupational and environmental health·2001
Same author

Self-reported quality of life across mood states in bipolar disorder.

Comprehensive psychiatry·2001
Same author

The Internal State Scale: replication of its discriminating abilities in a multisite, public sector sample.

Bipolar disorders·2001
Same journal

Are preference-weighted cancer-specific measures more sensitive than generic measures? A comparison of EQ-5D-5L, SF-6Dv2, FACT-8D and QLU-C10D in gastrointestinal cancers.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Development and Validation of a Brief Healthcare Insecurity Scale in a Sample of U.S. Adults Living with and without HIV.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

A Competency Framework for Health Technology Assessment Expertise: Results from a Delphi Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Physician-led Switching from Reference Biologics to Biosimilars: What is the Effect on selected Health-Related Outcomes and Costs for IBD Patients in Germany?

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Interpreting the Economic Value of TPEx in Recurrent or Metastatic HNSCC: The Importance of Decision Context, Utility Timing, and Treatment Burden.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
See all related articles

Developing robust modeling is crucial for extending lipid-lowering therapy trial benefits to diverse populations and long-term outcomes. Accurate risk stratification, considering LDL and HDL cholesterol, enhances these projections for coronary heart disease prevention.

Area of Science:

  • Cardiovascular Disease Research
  • Health Economics
  • Biostatistics

Background:

  • Clinical trials estimate lipid-lowering therapy benefits, but extending these findings requires advanced modeling.
  • Recent trials with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors highlight limitations in prior modeling approaches.
  • Real-world application necessitates methods to extrapolate trial data across different populations and timeframes.

Purpose of the Study:

  • To review key considerations for extending clinical trial data of lipid-lowering therapies to real-world scenarios.
  • To discuss modeling methodologies for projecting long-term and lifetime benefits of lipid modification.
  • To analyze the relationship between lipid reduction benefits and risk differences, particularly for coronary heart disease (CHD) prevention.

Related Experiment Videos

Main Methods:

  • Review of clinical trial data and modeling methodologies for lipid-lowering therapies.
  • Analysis of risk stratification factors, including LDL and HDL cholesterol levels and ratios.
  • Discussion of modeling approaches to extend treatment benefits beyond trial durations.

Main Results:

  • Effective risk stratification, incorporating both LDL and HDL cholesterol, is vital for accurate benefit projection.
  • Lipid reduction benefits are greater than predicted by baseline risk differences alone in individuals with established CHD or over age 58.
  • Modeling is essential to project benefits over time and across diverse populations.

Conclusions:

  • Advanced modeling methodologies are essential to translate clinical trial findings on lipid-lowering therapies into real-world health and economic benefits.
  • Risk stratification, emphasizing lipid profiles, is critical for personalized and effective CHD prevention strategies.
  • The findings have significant implications for primary prevention of CHD, especially in elderly populations.